SCHEMBL16187532

SCHEMBL16187532

C[C@H](N)c1ccc(OC2CCN(C(=O)OCc3ccccc3)C2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ ACACB O00763 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ LNPEP Q9UIQ6 1/20 0.50
▸ PDE4B Q07343 1/20 0.47
▸ HTT P42858 1/20 0.44
▸ PIK3CD O00329 1/20 0.44
▸ CTSL P07711 1/20 0.43
▸ CTSS P25774 1/20 0.43
▸ CTSK P43235 1/20 0.43
▸ BCL9 O00512 3/20 0.43
▸ CTNNB1 P35222 3/20 0.43
▸ F2 P00734 2/20 0.43
▸ F10 P00742 2/20 0.43
▸ GRIN2B Q13224 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15918506 1.00 SMN1; SMN2 (0.51) SMN1; SMN2CYP2C19ACACBNPC1RAB9A
Hydrochloric Acid SCHEMBL23141990 0.93 LNPEP (0.55) SMN1; SMN2CYP2C19ACACBNPC1RAB9A
Hydrochloric Acid SCHEMBL23141992 0.93 LNPEP (0.55) SMN1; SMN2CYP2C19ACACBNPC1RAB9A
SCHEMBL18176104 0.88 SMN1; SMN2 (0.47) SMN1; SMN2CYP2C19ACACBNPC1RAB9A
SCHEMBL15918410 0.85 SMN1; SMN2 (0.55) SMN1; SMN2CYP2C19NPC1RAB9ALNPEP
SCHEMBL16213720 0.84 ACACB (0.56) SMN1; SMN2ACACBNPC1RAB9A
SCHEMBL16481368 0.84 ACACB (0.59) ACACB
SCHEMBL16213721 0.84 ACACB (0.59) ACACB
SCHEMBL18176134 0.82 ACACB (0.54) ACACBPDE4BCTSLCTSSCTSK
SCHEMBL16187531 0.82 ACACB (0.54) ACACBPDE4BCTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2986604-B1 PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2017-12-20 — — EP disclosed
US-9169205-B2 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-27 — — US disclosed
US-9169205-B2 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-27 — — US disclosed
US-8962641-B2 Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-24 — — US disclosed
US-8962641-B2 Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-24 — — US disclosed
US-8877741-B2 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-04 — — US disclosed
US-8877741-B2 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-04 — — US disclosed
WO-2014170197-A1 PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-23 — — WO disclosed
US-20140315882-A1 PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-23 — — US disclosed
WO-2014056771-A1 NEW PYRROLIDINE DERIVATIVES AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315882-A1 PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF TYMP, APRT, TYMS SMN1; SMN2 3693/4885CYP2C19 449/4885ACACB 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback